Florida Cancer Specialists and Research Institute shared a post on LinkedIn:
“On November 15, 2024, the FDA approved a groundbreaking therapy for relapsed or refractory acute leukemia—marking a new era in cancer treatment.
We’re proud to share that the first-ever patient to receive this life-saving treatment was treated at our Sarasota Drug Development Unit in 2019, during a Phase 1 clinical trial.
As one of our three early-phase clinical trial sites statewide, we’ve been at the forefront of its development.
This innovative therapy, now available nationwide, has shown extraordinary results in targeting and treating this often difficult-to-treat leukemia, offering renewed hope to patients and their families.
Learn more about our participation in helping this drug become available to patients nationwide.”
